Northwest Biotherapeutics Stock Tanks 20% On Quarterly Results

Shares of Northwest Biotherapeutics, Inc. (NWBO) tanked over 20% on Tuesday morning after reporting its quarter results.

NWBO is currently trading at $1.43, down $0.39 or 21.4286%, on the Nasdaq, on a heavy volume of 8.5 million shares, above average volume of 2.3 million. The stock opened its trading at $1.71 after closing Monday's trading at $1.82. The stock has traded between $0.59 and $2.15 in the past 52 week period.

Revenues for the quarter were $403 thousand, up from $239 thousand last year. Net loss for the quarter widened to $14.2 million or $0.01 per share from $4.1 million or breakeven per share last year.

Northwest Biotherapeutics, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Follow RTT